BPOM Strengthens Downstreaming to Position Indonesia as Asia-Pacific ATMP Hub
Jakarta (ANTARA) - The Indonesian Food and Drug Authority (BPOM) is strengthening the downstreaming of stem cell therapy, moving from laboratory research to clinical application through the implementation of Good Manufacturing Practice (GMP). This effort is intended to establish Indonesia as a hub for the development of Advanced Therapy Medicinal Products (ATMP) in the Asia-Pacific region.
Head of BPOM, Taruna Ikrar, stated that globally, gene therapy, cell therapy, and ribonucleic acid (RNA)-based therapies are developing rapidly, with 4,164 products currently under development and 1-48 products having received approval in various countries. The market value of the ATMP industry is projected to more than double, rising from US$41.46 billion (IDR 697.73 trillion) in 2026 to US$86.76 billion (IDR 1,460 trillion) by 2031.
“This development shows that regenerative medicine is the future of healthcare. Indonesia must be prepared to be part of this progress through an adaptive regulatory system that simultaneously ensures patient safety,” he said in Jakarta on Saturday.
He noted that Indonesia has a significant opportunity to become one of the centres for ATMP and regenerative medicine development in the Asia-Pacific region. To achieve this, a robust ecosystem is required, ranging from research and regulation to industry and international collaboration.
However, he added that the greatest challenge in developing regenerative therapies is not merely scientific innovation, but also ensuring that every product possesses strong evidence of safety, efficacy, and quality.
“Many innovative therapies still face limitations regarding scientific evidence, dose standardisation, production process consistency, and long-term safety monitoring after public use,” he remarked.
Taruna explained that Indonesia currently possesses five GMP-certified stem cell processing facilities that are developing new medicinal products. Additionally, BPOM has provided GMP regulatory assistance to 43 stem cell facilities across Indonesia as part of the acceleration of national innovation development.
To accelerate the emergence of national health innovations, BPOM is developing an Academia-Business-Government (ABG) collaboration model. Through this approach, universities play a role in generating research, industry is responsible for downstreaming and production, while the government ensures the entire process meets safety, efficacy, and quality standards.
Currently, BPOM is collaborating with 186 universities in Indonesia and is supported by 270 GMP-certified pharmaceutical facilities in strengthening the national innovation ecosystem. The agency is also opening opportunities for investment and international cooperation in the development of regenerative therapies.
Taruna conveyed three key messages for the development of regenerative therapies in Indonesia. First, scientific discovery creates hope, but the application of GMP standards ensures products can be produced consistently; second, clinical evidence and pharmacovigilance serve as the foundation for long-term trust in innovative therapies. Third, the future of regenerative medicine depends on the ability to transform research results into products that are safe, consistent, and accessible to the public.
Chris Paulus, an Executive Board member of the American Board of Regenerative Medicine (ABRM), highlighted that the future of regenerative medicine is not determined by scientific progress alone. Furthermore, he stated it is also determined by the ability of all parties to build an integrated innovation ecosystem.
According to him, there are six main pillars for building such an ecosystem: strengthening education and training, standards and certification, centres of excellence, research and clinical translation, global collaboration, and the development of the biotechnology industry.
He noted that the largest investment required is in the education and training of human resources.
“We need to have an educated workforce. If we only develop biotechnology products, we will lack the educated workforce necessary to understand how to use these products safely and effectively,” said Chris.
Source: jawawa.id (https://jawawa.id/newsitem/bpom-strengthens-downstreaming-to-position-indonesia-as-asia-pacific-atmp-hub-1783162379)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5635467/bpom-kuatkan-hilirisasi-siapkan-ri-jadi-pusat-atmp-asia-pasifik), translated from Indonesian